tetano
Editor, Senior Moderator
J Med Virol
. 2020 Jul 15.
doi: 10.1002/jmv.26302. Online ahead of print.
Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Viveksandeep Thoguluva Chandrasekar[SUP] 1 [/SUP], Bhanuprasad Venkatesalu[SUP] 2 [/SUP], Harsh K Patel[SUP] 3 [/SUP], Marco Spadaccini[SUP] 4 [/SUP], Jacob Manteuffel[SUP] 2 [/SUP], Mayur Ramesh[SUP] 2 [/SUP]
Affiliations
Abstract
Treatment options for Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥ 18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95%CI: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36, 95% CI: 0.97-1.89). Adverse events were also higher in HCQ sub-group (OR: 3.88, 95% CI: 1.60 - 9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; HCQ; SARS-CoV-2; hydroxychloroquine; meta-analysis.
. 2020 Jul 15.
doi: 10.1002/jmv.26302. Online ahead of print.
Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Viveksandeep Thoguluva Chandrasekar[SUP] 1 [/SUP], Bhanuprasad Venkatesalu[SUP] 2 [/SUP], Harsh K Patel[SUP] 3 [/SUP], Marco Spadaccini[SUP] 4 [/SUP], Jacob Manteuffel[SUP] 2 [/SUP], Mayur Ramesh[SUP] 2 [/SUP]
Affiliations
- PMID: 32667699
- DOI: 10.1002/jmv.26302
Abstract
Treatment options for Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥ 18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95%CI: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36, 95% CI: 0.97-1.89). Adverse events were also higher in HCQ sub-group (OR: 3.88, 95% CI: 1.60 - 9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; HCQ; SARS-CoV-2; hydroxychloroquine; meta-analysis.